Fatima McKenzie, MD
Family Medicine · Oklahoma City, OKNPI 1659990232
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $516, more than ten times the $12 reported in 2020.
Across 32 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$71
- Sumitomo Pharma America, Inc.$68
- Novo Nordisk$64
- Lilly USA, LLC$59
- Boehringer Ingelheim$55
- Pfizer$54
- plus $171 from 8 others
What the payments were for
- Food & beverage$542100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 5 | $71 |
| Sumitomo Pharma America, Inc. | 4 | $68 |
| Novo Nordisk | 4 | $64 |
| Lilly USA, LLC | 3 | $59 |
| Boehringer Ingelheim | 3 | $55 |
| Pfizer | 3 | $54 |
| Exact Sciences | 3 | $44 |
| Globus Medical | 1 | $25 |
| AbbVie | 1 | $24 |
| Dynavax Technologies Corporation | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Merck | 1 | $12 |
How this compares
$542 in reported general payments places this provider in the 55th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $1,637 |
| Gabapentin | 32 | $556 |
| Amlodipine Besylate | 28 | $281 |
| Duloxetine Hcl | 14 | $273 |
| Metformin Hcl | 20 | $240 |
| Atorvastatin Calcium | 33 | $219 |
| Lisinopril | 22 | $101 |
| Losartan Potassium | 18 | $100 |
| Levothyroxine Sodium | 13 | $59 |
| Hydrochlorothiazide | 15 | $55 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Oklahoma City
- Alexander FrankOklahoma City$3.1M
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
- Jonathon KnoxOklahoma City$20K
- Steven SacketOklahoma City$17K
- Stanley CorleyOklahoma City$16K
- Teddy WebbOklahoma City$15K
- Judy MagnussonOklahoma City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.